An Interventional Study of Infigratinib in Children With Hypochondroplasia
Status:
ENROLLING_BY_INVITATION
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety, of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib, at one of two doses, of who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).